Wegovy and Ozempic made 2023 a revolutionary year for weight loss while radicle change is taking place as AI become a hot topic worldwide in the past year.
2023 also marks innovative drugs going global ushered in an outbreak after a time of recession in 2022 in China, there were 53 deals reached over out-licensing, co-development and JV with records of sizes renewed and numbers of out-licensing more than in-licensing.
In 2023, PharmaSources has also leveraged AI to write articles on the pharma topics, which casted an overview to Chinese pharmaceutical industry.
Summarizing the past, looking into the future, we have collected the most clicked articles at PharmaSources in the past year, hope this helps for the users in sourcing, developing and manufacturing the drug products in the year 2024.
We have sorted the content into 6 parts:
Created by AI
Chinese Pharmaceutical Market Overview by ChatGPT
Pharmaceutical International Cooperation Under the New Drug Policies in China By ChatGPT
China API Market Overview by ChatGPT
APIs in Demand
Demand for Antipyretic Drug Strikes Again, Restarting the Battle of iBuprofen
By Laoxue
The Rising Demand for Antioxidant Pharmaceuticals: A Promising Market
By David Orchard-Webb
The Ultimate Guide to API Pharmaceuticals
By PharmaSources
Famous GLP-1RA Outside of the Circle, and Rapid Development of Peptide CDMO
By Xiaobin
Emerging Markets
Global approvals of new innovative drugs by Chinese biotech companies
By Deborah Seah
South Africa Ups Registration of New Pharmaceutical Products
By Shem Oirere
Morocco pharmaceutical market outlook
By Shem Oirere
Industry Landscape
Latest Trends in Pharmaceutical Industry
By Muhammad Asim Niazi
Continuous Manufacturing Part 3: Continuous Manufacturing in China
By Deepak Hegde
Why the unit price gap of the weight loss drug GLP-1 is nearly ten times?
By Laoxue
Developing and Manufacturing Guides
Phenotypic Screening and Target-Based Drug Discovery: Is it Time to Unite?
By Neeta Ratanghayra










(All Rights Reserved)